Journal article
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease
MA Kamm, SB Hanauer, R Panaccione, JF Colombel, WJ Sandborn, PF Pollack, Q Zhou, AM Robinson
Alimentary Pharmacology and Therapeutics | Published : 2011
Abstract
Background Treatments that achieve sustainable steroid-free clinical remission in Crohn's disease are needed; however, long-term steroid-sparing efficacy data are limited. Aim To evaluate steroid-sparing efficacy and the impact of steroid discontinuation on adverse events during treatment of Crohn's disease with adalimumab in the phase III randomised, double-blind 1-year CHARM trial and for an additional 2 years in its open-label extension ADHERE. Methods Steroid-free remission and response and steroid-sparing (≥50% steroid dose reduction) remission rates were evaluated over 3 years in patients who were taking corticosteroids at CHARM baseline. Results Of 778 patients randomised in CHARM (in..
View full abstractGrants
Funding Acknowledgements
Declaration of personal interests: Michael A. Kamm has received honoraria for consultation from Abbott and Schering-Plough, and support for clinical research from Abbott. Stephen B. Hanauer has received honoraria for consultation and institutional support for clinical research from Abbott, Centocor Ortho Biotech, and UCB Pharma. Remo Panaccione has received honoraria for consultation from Abbott, Centocor Ortho Biotech and UCB Pharma, and support for clinical research from Abbott and UCB Pharma. Jean-Frederic Colombel has received honoraria for consultation and support for clinical research from Abbott, Centocor Ortho Biotech and UCB Pharma. William J. Sandborn has received honoraria for consultation and support for clinical research from Abbott, Centocor Ortho Biotech and UCB Pharma. Paul F. Pollack, Qian Zhou, Anne M. Robinson are employees of Abbott. Declaration of funding interests: This study was funded in full by Abbott. The preparation of this paper was funded by Abbott. Data analyses were undertaken by Winnie Lau who is an employee of Abbott. Writing support was provided by Eileen M. Burkart, PhD, and Laurinda A. Cooker, PhD, who are employees of Abbott, and Angela Cimmino, PharmD, who is an employee of JK Associates, Inc., and funded by Abbott.